Search for drugs:
Typing the drug name to query
ELOTUZUMAB
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- EMPLICITI does not prolong the QT interval to any clinically relevant extent when administered with lenalidomide and dexamethasone at the recommended dose or as monotherapy (at a dose 2 times the recommended dose).
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
4
24088
Other ADRs
3159
38378428
Odds Ratio = 2.018
Drug Property Information
ATC Code(s):
- L01XC23 - elotuzumab
- L01XC - Monoclonal antibodies
- L01X - OTHER ANTINEOPLASTIC AGENTS
- L01 - ANTINEOPLASTIC AGENTS
- L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Active Ingredient:ELOTUZUMAB
Active Ingredient UNII:1351PE5UGS
Drugbank ID:DB06317
PubChem Compound:N/ADIR Classification
CAS Number:
Dosage Form(s):injection, powder, lyophilized, for solution
Route(s) Of Administrator:intravenous
Daily Dose:
Chemical Structure: 
SMILE Code:
Reference
1: Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma.
[Passey Chaitali,Darbenzio Raymond,Jou Ying-Ming,Lynch Mark,Gupta Manish]Cancer Chemother Pharmacol,2016 Dec;78(6):1237-1244. PMID: 27796540
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.